Steven Cohen's MLTX Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 1.37 M shares of MoonLake Immunotherapeutics (MLTX) worth $25.51 M, representing 0.03% of the portfolio. First purchased in 2022-Q3, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in MLTX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 762,700 shares. Largest reduction occurred in Q4 2022, reducing 335,000 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's MoonLake Immunotherapeutics (MLTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly MoonLake Immunotherapeutics (MLTX) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +596,018 | Add 77.15% | 1.37 M | $18.64 |
| Q4 2025 | +762,700 | Add 7782.65% | 772,500 | $13.18 |
| Q3 2025 | -176,768 | Reduce 94.75% | 9,800 | $7.17 |
| Q2 2025 | +186,568 | New Buy | 186,568 | $47.20 |
| Q1 2025 | -98,719 | Sold Out | 0 | $0.00 |
| Q4 2024 | +98,719 | New Buy | 98,719 | $54.15 |
| Q2 2023 | -29,748 | Sold Out | 0 | $0.00 |
| Q1 2023 | +29,748 | New Buy | 29,748 | $21.39 |
| Q4 2022 | -335,000 | Sold Out | 0 | $0.00 |
| Q3 2022 | +335,000 | New Buy | 335,000 | $7.76 |
Steven Cohen's MoonLake Immunotherapeutics Investment FAQs
Steven Cohen first purchased MoonLake Immunotherapeutics (MLTX) in Q3 2022, acquiring 335,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held MoonLake Immunotherapeutics (MLTX) for 10 quarters since Q3 2022.
Steven Cohen's largest addition to MoonLake Immunotherapeutics (MLTX) was in Q4 2025, adding 772,500 shares worth $10.18 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 1,368,518 shares of MoonLake Immunotherapeutics (MLTX), valued at approximately $25.51 M.
As of the Q1 2026 filing, MoonLake Immunotherapeutics (MLTX) represents approximately 0.03% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in MoonLake Immunotherapeutics (MLTX) was 1,368,518 shares, as reported at the end of Q1 2026.